Please enable JavaScript to continue using this application.

Compare $GLUE vs $RIGL | Chartloom

Compare

$GLUE vs $RIGL

Monte Rosa Therapeutics Inc · Rigel Pharmaceuticals Inc

GLUE

Monte Rosa Therapeutics Inc

RIGL

Rigel Pharmaceuticals Inc

Compare $GLUE vs $RIGL

Comparing Monte Rosa Therapeutics Inc and Rigel Pharmaceuticals Inc

GLUEMonte Rosa Therapeutics Inc

RIGLRigel Pharmaceuticals Inc

GLUEMonte Rosa Therapeutics Inc

Market cap

$870M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

21.85x

Rev growth (TTM)

-83.9%

YTD performance

-32.7%

52W performance

33.6%

FCF yield

-3.7%

RIGLRigel Pharmaceuticals Inc

Market cap

$908M

P/E (TTM)

2.98x

Forward P/E (NTM)

15.85x

Forward P/S (NTM)

2.61x

Rev growth (TTM)

3.3%

YTD performance

17.3%

52W performance

70.7%

FCF yield

1.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GLUE

RIGL

Detailed metrics comparison

GLUE

Monte Rosa Therapeutics Inc

RIGL

Rigel Pharmaceuticals Inc

Market Cap

GLUE$870M

RIGL$908M

Enterprise Value

GLUE$780M

RIGL$886M

Price

GLUE$10.30

RIGL$49.08

P/E Ratio

GLUEN/A

RIGL2.98x

P/S Ratio

GLUE30.29x

RIGL3.28x

EV/Sales

GLUE27.15x

RIGL3.20x

EV/EBITDA

GLUE47.84x

RIGL9.50x

P/B Ratio

GLUE1.84x

RIGL2.07x

P/FCF Ratio

GLUEN/A

RIGL100.69x

EV/FCF

GLUE-24.32x

RIGL98.29x

PEG Ratio

GLUEN/A

RIGL0.01x

Forward P/E (NTM)

GLUEN/A

RIGL15.85x

Forward P/S (NTM)

GLUE21.85x

RIGL2.61x

Revenue (TTM)

GLUE$29M

RIGL$277M

Revenue Growth (YoY)

GLUE-83.9%

RIGL3.3%

Forward Rev Growth

GLUE-58.1%

RIGL21.9%

Gross Margin (TTM)

GLUE0.0%

RIGL91.4%

Operating Margin (TTM)

GLUE0.0%

RIGL31.4%

EBITDA Margin (TTM)

GLUE-604.8%

RIGL32.4%

Net Margin (TTM)

GLUE-560.9%

RIGL116.3%

FCF Margin (TTM)

GLUE-111.7%

RIGL3.3%

Net Income (TTM)

GLUE$-161M

RIGL$322M

FCF (TTM)

GLUE$-32M

RIGL$9M

EPS (TTM)

GLUE-$1.59

RIGL$16.45

ROE (TTM)

GLUE-4331.0%

RIGL96.5%

ROA (TTM)

GLUE-2759.0%

RIGL72.3%

ROIC (TTM)

GLUE-4331.0%

RIGL84.1%

Cash

GLUE$90M

RIGL$61M

Debt

GLUE$0

RIGL$39M

Net Cash/Debt

GLUE$90M

RIGL$22M

Current Ratio (TTM)

GLUE10.58x

RIGL1.94x

Quick Ratio (TTM)

GLUE10.49x

RIGL1.58x

Debt/Equity (TTM)

GLUE0.00x

RIGL0.09x

Debt/Assets (TTM)

GLUE0.0%

RIGL0.0%

Interest Coverage (TTM)

GLUEN/A

RIGLN/A

Net Debt/EBITDA (TTM)

GLUE0.00x

RIGL0.00x

Beta

GLUE1.34

RIGL1.26

52W Performance

GLUE33.6%

RIGL70.7%

YTD Performance

GLUE-32.7%

RIGL17.3%

% from 52W High

GLUE-60.0%

RIGL-6.0%

% from 52W Low

GLUE34.7%

RIGL96.7%

Asset Turnover (TTM)

GLUE0.05x

RIGL0.62x

FCF Yield (TTM)

GLUE-3.7%

RIGL1.0%

Earnings Yield (TTM)

GLUE-18.5%

RIGL35.5%

Dividend Yield (TTM)

GLUEN/A

RIGLN/A

Rule of 40

GLUE-195.5

RIGL6.6

EV/GP/RG

GLUEN/A

RIGL0.13

Ticker research

View GLUE research View RIGL research

Metric	GLUE Monte Rosa Therapeutics Inc	RIGL Rigel Pharmaceuticals Inc
Market & Valuation
Market Cap	$870M	$908M
Enterprise Value	$780M	$886M
Price	$10.30	$49.08
P/E Ratio	N/A	2.98x
P/S Ratio	30.29x	3.28x
EV/Sales	27.15x	3.20x
EV/EBITDA	47.84x	9.50x
P/B Ratio	1.84x	2.07x
P/FCF Ratio	N/A	100.69x
EV/FCF	-24.32x	98.29x
PEG Ratio	N/A	0.01x
Forward P/E (NTM)	N/A	15.85x
Forward P/S (NTM)	21.85x	2.61x
Revenue & Growth
Revenue (TTM)	$29M	$277M
Revenue Growth (YoY)	-83.9%	3.3%
Forward Rev Growth	-58.1%	21.9%
Profitability
Gross Margin (TTM)	0.0%	91.4%
Operating Margin (TTM)	0.0%	31.4%
EBITDA Margin (TTM)	-604.8%	32.4%
Net Margin (TTM)	-560.9%	116.3%
FCF Margin (TTM)	-111.7%	3.3%
Net Income (TTM)	$-161M	$322M
FCF (TTM)	$-32M	$9M
EPS (TTM)	-$1.59	$16.45
ROE (TTM)	-4331.0%	96.5%
ROA (TTM)	-2759.0%	72.3%
ROIC (TTM)	-4331.0%	84.1%
Financial Health
Cash	$90M	$61M
Debt	$0	$39M
Net Cash/Debt	$90M	$22M
Current Ratio (TTM)	10.58x	1.94x
Quick Ratio (TTM)	10.49x	1.58x
Debt/Equity (TTM)	0.00x	0.09x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.34	1.26
52W Performance	33.6%	70.7%
YTD Performance	-32.7%	17.3%
% from 52W High	-60.0%	-6.0%
% from 52W Low	34.7%	96.7%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.62x
FCF Yield (TTM)	-3.7%	1.0%
Earnings Yield (TTM)	-18.5%	35.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-195.5	6.6
EV/GP/RG	N/A	0.13
Ticker research	View GLUE research	View RIGL research

Valuation

P/E Ratio

RIGL

2.98x

P/S Ratio

RIGL

3.28x

GLUE

30.29x

EV/FCF

GLUE

-24.32x

RIGL

98.29x

Growth & revenue

Revenue Growth TTM

RIGL

3.3%

GLUE

-83.9%

Forward Revenue Growth

RIGL

21.9%

GLUE

-58.1%

Profitability & performance

Gross Margin

RIGL

91.4%

GLUE

0.0%

ROE

RIGL

96.5%

GLUE

-4331.0%

FCF Yield %

RIGL

1.0%

GLUE

-3.7%

52-Week Performance

RIGL

70.7%

GLUE

33.6%

Detailed metrics comparison

GLUE

Monte Rosa Therapeutics Inc

RIGL

Rigel Pharmaceuticals Inc

Market Cap

GLUE$870M

RIGL$908M

Enterprise Value

GLUE$780M

RIGL$886M

Price

GLUE$10.30

RIGL$49.08

P/E Ratio

GLUEN/A

RIGL2.98x

P/S Ratio

GLUE30.29x

RIGL3.28x

EV/Sales

GLUE27.15x

RIGL3.20x

EV/EBITDA

GLUE47.84x

RIGL9.50x

P/B Ratio

GLUE1.84x

RIGL2.07x

P/FCF Ratio

GLUEN/A

RIGL100.69x

EV/FCF

GLUE-24.32x

RIGL98.29x

PEG Ratio

GLUEN/A

RIGL0.01x

Forward P/E (NTM)

GLUEN/A

RIGL15.85x

Forward P/S (NTM)

GLUE21.85x

RIGL2.61x

Revenue (TTM)

GLUE$29M

RIGL$277M

Revenue Growth (YoY)

GLUE-83.9%

RIGL3.3%

Forward Rev Growth

GLUE-58.1%

RIGL21.9%

Gross Margin (TTM)

GLUE0.0%

RIGL91.4%

Operating Margin (TTM)

GLUE0.0%

RIGL31.4%

EBITDA Margin (TTM)

GLUE-604.8%

RIGL32.4%

Net Margin (TTM)

GLUE-560.9%

RIGL116.3%

FCF Margin (TTM)

GLUE-111.7%

RIGL3.3%

Net Income (TTM)

GLUE$-161M

RIGL$322M

FCF (TTM)

GLUE$-32M

RIGL$9M

EPS (TTM)

GLUE-$1.59

RIGL$16.45

ROE (TTM)

GLUE-4331.0%

RIGL96.5%

ROA (TTM)

GLUE-2759.0%

RIGL72.3%

ROIC (TTM)

GLUE-4331.0%

RIGL84.1%

Cash

GLUE$90M

RIGL$61M

Debt

GLUE$0

RIGL$39M

Net Cash/Debt

GLUE$90M

RIGL$22M

Current Ratio (TTM)

GLUE10.58x

RIGL1.94x

Quick Ratio (TTM)

GLUE10.49x

RIGL1.58x

Debt/Equity (TTM)

GLUE0.00x

RIGL0.09x

Debt/Assets (TTM)

GLUE0.0%

RIGL0.0%

Interest Coverage (TTM)

GLUEN/A

RIGLN/A

Net Debt/EBITDA (TTM)

GLUE0.00x

RIGL0.00x

Beta

GLUE1.34

RIGL1.26

52W Performance

GLUE33.6%

RIGL70.7%

YTD Performance

GLUE-32.7%

RIGL17.3%

% from 52W High

GLUE-60.0%

RIGL-6.0%

% from 52W Low

GLUE34.7%

RIGL96.7%

Asset Turnover (TTM)

GLUE0.05x

RIGL0.62x

FCF Yield (TTM)

GLUE-3.7%

RIGL1.0%

Earnings Yield (TTM)

GLUE-18.5%

RIGL35.5%

Dividend Yield (TTM)

GLUEN/A

RIGLN/A

Rule of 40

GLUE-195.5

RIGL6.6

EV/GP/RG

GLUEN/A

RIGL0.13

Ticker research

View GLUE research View RIGL research

Metric	GLUE Monte Rosa Therapeutics Inc	RIGL Rigel Pharmaceuticals Inc
Market & Valuation
Market Cap	$870M	$908M
Enterprise Value	$780M	$886M
Price	$10.30	$49.08
P/E Ratio	N/A	2.98x
P/S Ratio	30.29x	3.28x
EV/Sales	27.15x	3.20x
EV/EBITDA	47.84x	9.50x
P/B Ratio	1.84x	2.07x
P/FCF Ratio	N/A	100.69x
EV/FCF	-24.32x	98.29x
PEG Ratio	N/A	0.01x
Forward P/E (NTM)	N/A	15.85x
Forward P/S (NTM)	21.85x	2.61x
Revenue & Growth
Revenue (TTM)	$29M	$277M
Revenue Growth (YoY)	-83.9%	3.3%
Forward Rev Growth	-58.1%	21.9%
Profitability
Gross Margin (TTM)	0.0%	91.4%
Operating Margin (TTM)	0.0%	31.4%
EBITDA Margin (TTM)	-604.8%	32.4%
Net Margin (TTM)	-560.9%	116.3%
FCF Margin (TTM)	-111.7%	3.3%
Net Income (TTM)	$-161M	$322M
FCF (TTM)	$-32M	$9M
EPS (TTM)	-$1.59	$16.45
ROE (TTM)	-4331.0%	96.5%
ROA (TTM)	-2759.0%	72.3%
ROIC (TTM)	-4331.0%	84.1%
Financial Health
Cash	$90M	$61M
Debt	$0	$39M
Net Cash/Debt	$90M	$22M
Current Ratio (TTM)	10.58x	1.94x
Quick Ratio (TTM)	10.49x	1.58x
Debt/Equity (TTM)	0.00x	0.09x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.34	1.26
52W Performance	33.6%	70.7%
YTD Performance	-32.7%	17.3%
% from 52W High	-60.0%	-6.0%
% from 52W Low	34.7%	96.7%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.62x
FCF Yield (TTM)	-3.7%	1.0%
Earnings Yield (TTM)	-18.5%	35.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-195.5	6.6
EV/GP/RG	N/A	0.13
Ticker research	View GLUE research	View RIGL research